Posted by Michael Wonder on 02 Nov 2022
GSK’s respiratory syncytial virus older adult vaccine candidate granted priority review by US FDA
2 November 2022 - US FDA has set a Prescription Drug User Fee Act action date of 3 May 2023.
GSK today announced that the US FDA has accepted a biologics license application and granted priority review for its respiratory syncytial virus older adult vaccine candidate.
